ARx, LLC., was founded in 2005, as a wholly owned cGMP subsidiary of Adhesives Research Inc. Recognizing the potential for soluble thin films to deliver active pharmaceutical ingredients, ARx became a global leader of the dosage form with the launch of over-the-counter pharmaceutical products and has been a commercial drug manufacturer for over 10 years. Since the technology first debuted, the thin film dosage form has expanded to include buccal and sublingual delivery applications and ARx has shifted its focus to prescription applications in both the branded and generic drug markets.
Through Adhesives Research, ARx is able to leverage over 50 years of drug formulation and coating expertise, as well as 30 years’ experience in the development and manufacture of adhesive formulations for the transdermal patch industry. The relationships formed over the years have provided us with a unique advantage and deep understanding of the drug delivery systems and market needs.
Established in 1961, the humble beginnings of Adhesives Research originated in a converted garage to develop and supply specialty adhesive-coated materials and processing equipment to meet the evolving needs of the graphics arts label market. Through several moves and expansions, Adhesives Research grew steadily, developing new capabilities and technologies that enabled the company to address the unmet needs of new markets. Rapid growth led to facility expansions to include the U.S., South America (1980), Europe (1999), and Asia (2000). With headquarters in Glen Rock, Pennsylvania, and Limerick, Ireland, today the company’s facilities span over 250 acres, cover over 300,000+ square feet of development and manufacturing space and employ approximately 300 associates. Today ARx remains an independent company, committed to working with customers as partners in the development of application-specific products that fill their unmet material needs.